23 November 2021 - - US-based biotechnology company Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has announced changes to its board of directors including the addition of June Lee, M.D., and the transition of JJ Kang, Ph.D., who will be stepping down after five years of service.

Dr. Lee was most recently founder and CEO of Esker Therapeutics. She previously served as executive vice president, Chief Development officer and chief operating officer of MyoKardia from 2017 to 2020.

In this role, Dr. Lee built and led a world-class global development organization to advance novel therapies for cardiomyopathies through clinical development.

She was previously also therapeutic area head for early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech.

She currently serves on the advisory board for Johns Hopkins University Center for Therapeutic Translation, serves as a Board director for Eledon Pharmaceuticals Inc. and for GenEdit, and is a member of the Scientific advisory board for Foresite Labs. Dr. Lee completed a Bachelor of Science in chemistry at Johns Hopkins University, an M.D. at the School of Medicine at the University of California, Davis, and her clinical training in internal medicine and pulmonary and critical care at UCLA and UCSF.

In addition, Dr. Kang has decided to resign from Tenaya's Board to focus on her current role as CEO of Appia Bio and as a Venture Partner at The Column Group. Dr. Kang helped launch Tenaya in 2016 and has since served as a valued Board member. She also served in the capacity of interim Tenaya president for the first two years of the company's history.

Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease.

Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.